03 dec: Indre værdi af SmallCap Danmark A/S er opgjort til 21,2 kr. pr. a..
03 dec: NTR Holding A/S: Finanskalender
03-12-2018 03:17:50

Genmab to Hold R&D Update and 2018 ASH Data Review Meeting

Relateret indhold
18 jan - 
Fredagens aktier: Flagrende Pandora fløj højest i stige..
18 jan - 
Aktier/middag: Pandora genvinder pusten og topper C25
11 jan - 
Aktier/middag: Danske Bank klarer skærene i afdæmpet ma..
Relateret debat
18 jan - 
Du børge spørge din model om talstørrelser, og om 2018 ..
18 jan - 
I så fald.....bla bla bla....... Undskyld mig, men hvor..
18 jan - 
i så fald skal genmab ned mod 345 området for at lave b..

Media Release

  • Event to be held today in San Diego, California

  • Independent experts to discuss data presented at the 2018 ASH Annual Meeting

  • Meeting to be webcast live and archived on www.genmab.com

Copenhagen, Denmark; December 3, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN) will hold a R&D Update and 2018 ASH Data Review Meeting today, December 3, 2016 at 8:00 PM Pacific Time (5:00 AM CET / 4:00 AM GMT on 4 December).  The event will take place in San Diego, California, and will also be webcast live and archived on the company’s website.  The meeting will include presentations by independent experts on data from daratumumab studies presented at the 60th Annual Meeting of the American Society of Hematology (ASH), including some key aspects of the Phase III MAIA study. Genmab speakers will also discuss pre-clinical data from Genmab’s DuoBody-CD3xCD20 and DuoHexaBody-CD37 programs presented at ASH, as well as the company’s progress and key goals for 2019.

The following cancer experts and senior Genmab staff will be at the event:

Independent experts:

  • Dr. Meletios A. Dimopoulos, National and Kapodistrian University of Athens, School of Medicine
  • Dr. Nizar Bahlis, Arnie Charbonneau Cancer Institute, University of Calgary
  • Dr. Saad Usmani, University of North Carolina at Chapel Hill, Levine Cancer Institute

Genmab:

  • Dr. Jan van de Winkel, President and CEO, Genmab
  • Dr. Judith Klimovsky, Executive Vice President and CDO, Genmab
  • Dr. Kate Sasser, Corporate Vice President, Translational Research, Genmab

Key daratumumab abstracts to be discussed during the event include:

LB-2: Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

Abstract 156: One-year Update of a Phase 3 Randomized Study of Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) in Patients (Pts) With Transplant-ineligible Newly Diagnosed Multiple Myeloma (NDMM): ALCYONE

Abstract 151: Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from GRIFFIN, a Phase 2 Randomized Study of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide, and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma Eligible for High-Dose Therapy and Autologous Stem Cell Transplantation

Abstract 1996: Three-Year Follow Up of the Phase 3 POLLUX Study of Daratumumab Plus Lenalidomide and Dexamethasone Versus Lenalidomide and Dexamethasone Alone in Relapsed or Refractory Multiple Myeloma

Abstract 3270: Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib, and Dexamethasone in First Relapse Patients: Two-Year Update of CASTOR

Abstract 1995: Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-label, Multicenter, Phase 1b Study (PAVO)

The event will take place at the Manchester Grand Hyatt in San Diego, California, Harbor G&H. Those wishing to attend in person may register on site.

The event can also be attended via webcast. To view this webcast visit: https://edge.media-server.com/m6/p/8gdmxojt. Webcast viewers may submit questions during the Q&A portion of the live webcast via the webcast player. An archive of the webcast will be available on Genmab’s website. The webcast will be conducted in English.

This meeting is not an official program of the ASH Annual Meeting.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications.  Daratumumab is in clinical development for additional multiple myeloma indications and other blood cancers.  A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies and the HexElect™ platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products.  Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

Contact:          

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communication

T: +45 33 44 77 20; E: rcg@genmab.com

This Media Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody™; HexElect™; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

Media Release no. 15

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment

logo.jpg

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
15 jan
GEN
Det er flot. Har I overvejet at shorterne sidder og laver tegninger til jer. Genmab vil være eventdr..
6
18 jan
GEN
I så fald.....bla bla bla.......   Undskyld mig, men hvor ser du lige sammenligningen mellem Pandora..
4
15 jan
GEN
Det er vist dig, der er i panik.
4
15 jan
GEN
Mon ikke snart vi får stigninger der vil noget, mon ikke der er et firma der ikke gider at betale ro..
2
15 jan
GEN
Det er modellen fra minutchartet, du har analyseret for signaler, går jeg ud fra ;)   Du skulle nok ..
2
15 jan
GEN
jeg mente 1000-1025 var toppen i december, men den gik lidt mere op grundet januar rally, men det se..
1
14 jan
GEN
Det mere om det ikke blot er panik. Jeg har meget svært ved at tro, når de har fået det godkendt og ..
1

Aktier/tendens: Pandora tager opmærksomhed i ventet neutral start

21-01-2019 08:07:45
Pandora kan mandag endnu en gang være i investorernes søgelys, på en dag hvor der er udsigt til en tæt på uændret åbning for det danske eliteindeks, C25.Smykkekoncernen har været genstand for stor aktivitet fra årets start. Fredag endte aktien øverst i C25 med en stigning på 5,7 pct. til 275,10 kr., mens den indledte sidste uge med et dyk på 6 pct. For året som helhed kan aktien notere et plus på ..

Analytiker: Højere DSV-kurs kan holde konkurrenter fra Panalpina-citat

18-01-2019 13:59:53
Der har været god gænge i DSV-aktien, siden at det onsdag kom frem, at transportgiganten har lagt et bud på den schweiziske konkurrent Panalpina.Kursen er nu 9 pct. højere end før buddet, og det øger chancen for, at DSV løber med selskabet. Sådan lyder det ifølge Jyllands-Posten Finans fra Nordea i en analyse.DSV har nemlig tilbudt både kontantbetaling og DSV-aktier for selskabet - og med den stig..

Jyske Bank mister troen på Pandora

18-01-2019 09:54:35
Jyske Bank ser et mindre potentiale i Pandora efter et svagt julesalg. Banken skærer kursmålet med en fjerdedel, så det nu lyder på 300 kr.Torsdag kom der tal fra den amerikanske smykkekæde Signet Jewels, og heraf fremgik det specifikt, at julesalget af Pandora-smykker fra smykkekoncernens amerikanske forhandlere, Jared, var faldet. Julesalget omfatter både november, december og den første uge af ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Aktier/tendens: Pandora tager opmærksomhed i ventet neutral start
2
Ambu lancerer nyt produkt
3
Parken-formand: Købstilbud kom ind ad bagdøren
4
Pandora/Citi: Anbefalingen sænkes til "neutral"
5
Brexit: Theresa May på kollisionskurs med parlamentsmedlemmer - citat

Relaterede aktiekurser

Genmab A/S 1.032,50 1,4% Stigning i aktiekurs

Køb- og salgssignaler

  • Trend
  • Pengemaskinen

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
21. januar 2019 09:36:29
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190108.3 - EUROWEB5 - 2019-01-21 09:36:29 - 2019-01-21 09:36:29 - 1 - Website: OKAY